Biopeople

Strategic growth driver

Strategic growth driver

29.09.2014 - After serving on the board since January 2014 at Abcam plc, Alan Hirzel has been appointed as the new CEO of Abcam – a leading provider of innovative protein research tools and services.

Alan Hirzel will succeed Jonathan Milner, the long-serving Chief Executive and co-Founder of Abcam. Hirzel brings an impressive combination of a strong scientific background, global business and leadership experience, and consumer knowledge. Hirzel takes on the role of CEO after having spent the last year as Chief Marketing Officer. As CMO he was responsible for the company’s branding, product portfolio and online consumer offering, and worked closely with Jonathan Milner to develop Abcam’s strategic vision.

http://www.european-biotechnology-news.com/people/bio-people/2014/alan-hirzel.html

26.09.2014 Drug discovery and development company Novimmune SA has named Adrian Mills as the company’s new CBO and member of the Executive Committee.

© Novimmune SA

Adrian Mills will be leading Novimmune’s commercial development activities as well as business development. With over 20 years of experience as a pharmaceutical executive, he has a particular focus on the commercialisation of orphan drugs. Mills joins Novimmune after 13 years at GlaxoSmithKline (GSK), where he held several strategic and operational positions in Europe and SE Asia. Most recently he was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Mills worked in management consulting and investment banking in the life sciences sector.

23.09.2014 Reneuron Group, a leading UK-based stem cell therapy company, has appointed Olav Hellebø as their new Chief Executive Officer.

© Reneuron

A highly experienced pharmaceutical executive, Hellebø has broad commercial experience gained at both major pharmaceutical and small biotechnology companies in the fields of clinical development, commercialism and marketing of new therapeutics. Before taking on the role of CEO at ReNeuron, Hellebø held the position of CEO at Clavis Pharma ASA, a Norwegian company specialising in oncology. Prior to Clavis, Hellebø was at the helm of UCB Pharma and head of the UK operations of Novartis. Hellebø began his pharmaceutical career in 1992 at Schering-Plough, where he held senior commercial roles in Europe and the US.

22.09.2014 Frank Ubags has joined Cevec Pharmaceuticals to lead its new CMO initiative.

© Cevec Pharmaceuticals

He will replace Rainer Lichtenberger as Managing Director and will channel the extension of Cevec’s offerings to customers and production of up to Phase II cGMP material in CAP cells. Ubags has served more than 35 years in senior positions at firms that include Rhein Biotech, Kiadis Pharma and Scil Proteins. Ubags managed Scil Proteins CMO activities, and also initiated the sale of Scil Proteins Production to Wacker Biotech.

16.09.2014 David Veitch has been appointed as Chief Commercial Officer of Basilea Pharmaceutica International Ltd.

© Basilea Pharmaceutica Ltd.

As a member of the management committee, David Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access. Veitch has over 25 years of international commercial experience in the pharmaceutical industry. Before joining Basilea, he led cross-functional organisations at the country and European level and was responsible for the launch of numerous brands across several therapeutic areas. From 1996 ­to 2011, he was President European Operations at Savient Pharmaceuticals. Veitch has also held various positions at Bristol-Myers Squibb UK and Europe. His last position at the company was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, where he led the commercial organisation for the region with a focus on specialty care brands.

15.09.2014 Nektarios Tavernarakis, notable researcher with a focus on cell death, neurodegeneration and aging, has been elected a member of The Academy of Europe (Academia Europaea).

© Academia Europaea

Tavernakis is Research Director at the Institute of Molecular Biology and Biotechnology (IMBB) of the Foundation of Research and technology Hellas (FORTH), and professor at the Medical School of the University of Crete, has been elected a member of the Academy of Europe (Academia Europaea). Tavernarakis’ research focuses on cell death, neurodegeneration and ageing. He has received several notable scientific prizes for his scientific accomplishments. Among his accolades are the Academic Excellence Prize from the Empeirikeion Foundation and the Science Excellence Award, General Secretariat for Research and Technology, Ministry of Education both awarded in Greece in 2012. Before joining IMBB-FORTH as Executive Researcher in 2001, Tavernarakis worked as a Research Associate at Rutgers University, USA. Tavernarakis is also an elected member of EMBO.

04.09.2014 Miriam Monge has been named Director of Marketing for pharma and biotech supplier Sartorius Stedim Biotech’s Integrated Solutions unit.

© Sartorius Stedim Biotech

Monge makes the switch from UK consultancy Biopharm Services where she acted as Vice President of Sales & Marketing. She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice.

02.09.2014 The former Chair of the Supervisory Board of Dutch clinical-stage immunotherapy company ISA Pharmaceuticals B.V., Ronald Loggers will in the future head the company's daily business activities as CEO.

© ISA Pharmaceuticals

Once Managing Director of ISA’s investor Multi­fund B.V., Loggers took over as acting CEO in June. The new Chief Executive, who holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from the Delft University of Technology, has served on boards in the past, and was Managing Director at Pearle Benelux. Prior to that, he worked for McKinsey & Company and Fokker Aircraft.

28.08.2014 Long-time CEO of Santen Inc. Adrienne Graves has joined the Board of Directors at French ophthalmic company Nicox S.A.

© Nicox

In tandem with Luzi von Bidder and Les Kaplan, who are also freshly appointed to the Board, Graves will be replacing Vaughn Kailian and Vince Anido, who are both stepping down. Before taking on duties as President and CEO at Santen – the US arm of Japan's largest ophthalmic pharmaceutical company – Graves spent nine years with Alcon Laboratories, where her roles included that of Director of International Ophthal­mology. She currently serves as Director on several corporate boards, among them Akorn Inc., TearLab Corporation, Aerpio, Encore Vision and Envisia Therapeutic.

25.08.2014 Gene and cell therapy company Oxford Biomedica plc has appointed Paul Blake as Chief Development Officer.

© Oxford Biomedica

Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a Canada-based biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. Paul was a Member of the Board at Memory Pharmaceutical, Inc. and founding Board member of Protez Pharmaceuticals, which were later acquired by Roche and Novartis, respectively. He was also Director of ViaCell and held senior management positions at Cephalon Inc. He is a fellow of the Royal College of Physicians, a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and also a fellow of the American College of Clinical Pharmacology.

Effective September 1st, Blake will take over responsibility for the clinical development of Oxford Biomedica’s therapy pipeline. Blake will also remain a member of the company’s board, which he joined in early 2010.

22.08.2014 Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.

© RSSL

Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

1/21Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products